by Jeito Life | 29 Nov Tue | English
Deal validates Jeito’s unique investment model of selecting high-quality assets developed by world-leading teams in therapeutic areas with high unmet need Paris, France, November 29th 2022 – Jeito Capital (“Jeito”), the largest fully independent...
by Manon FRACHON | 22 Nov Tue | English
Jeito Capital co-leads oversubscribed EUR 50 million Series C financing with Brandon Capital CatalYm is developing a new class of anti-cancer immunotherapies, which have already demonstrated initial promising clinical results in advanced-stage solid tumor patients...
by Manon FRACHON | 2 Nov Wed | English
Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph Capital HI-Bio is a San Francisco-based clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases Investment...
by Manon FRACHON | 25 Oct Tue | English
Bastien Renaud is appointed Chief Financial Officer Evaldo Bifulco, Head of Compliance & Risk, and Charlotte Formont, Associate Counsel, also joined Jeito Capital in 2022 Paris, France, October 26, 2022 – Jeito Capital (“Jeito”), a leading...
by Jeito Life | 11 Oct Tue | English
Aarhus, Denmark, 11 October 2022 – NMD Pharma A/S, a clinical stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, today reported positive top-line results from a Phase I/IIa clinical trial of NMD670,...
by Jeito Life | 14 Sep Wed | English
Paris, France, September 14, 2022 – Jeito Capital (“Jeito”), a leading independent Private Equity firm dedicated to biotech and biopharma, announced today that it has co-led a Series B financing round in SparingVision, a privately held French biotech...
Recent Comments